How Will the Top Line Change for Repligen in 2014?

Repligen will lose an important royalty revenue stream from Bristol-Myers Squibb this year. How will that affect its top line for investors?

Jan 9, 2014 at 11:42AM

The first full week of investing in 2014 is almost in the books. However, not all companies will face the same amount of uncertainty over the next 12 months. Bioprocessing products company Repligen (NASDAQ:RGEN), which supplies consumable products to pharmaceutical companies manufacturing monoclonal antibodies, will surely keep shareholders on the edge of their seats. What's contributing to the ambiguity for the growing life sciences company? A generous royalty stream on U.S. sales of the rheumatoid arthritis drug Orencia from Bristol-Myers Squibb's (NYSE:BMY) ended -- as initially agreed upon -- on the last day of 2013.

Despite the loss of Orencia royalties, management is still guiding for 10%-15% product revenue growth, gross product margin of 55%, and operating margin north of 15% this year. Nonetheless, the royalties made a substantial contribution to total revenue in 2013 -- an estimated 25%! That means investors will need to use caution when comparing financial metrics and numbers achieved this year to those from prior year periods. Rather than panic with the release of each quarterly update, let's use the latest guidance from management and some simple arithmetic to analyze how the top and bottom lines will likely look for Repligen in 2014. Today, we'll start with the top line.

Estimating 2014 revenue

The first step in understanding how revenue will change in a post-Orencia and Bristol-Myers Squibb world is visualizing how the royalty stream compared to product revenue and the percent of total revenue it represented.





Orencia Royalties

$17.87 million

$14.75 million

$10.25 million

Product Revenue

$48 million

$41.8 million

$16.4 million

Total Revenue

$67 million

$62.3 million

$27.3 million

Orencia % of Total Revenue




Source: SEC filings, Piper Jaffray Conference Presentation, Author's calculations

Management has guided for $19-$21 million in total royalties and other revenue in 2013. Therefore, by subtracting the $1.124 million received from Pfizer in upfront and milestone payments for a spinal muscular atrophy licensing agreement and using the low end of guidance, we can assume that the remainder will be generated from Orencia royalties. The estimated royalty revenue in the table above would require Orencia to notch U.S. sales of roughly $943 million in 2013, or a growth rate of roughly 18% compared to the prior year.

Considering that (1) U.S. sales of Orencia through the first nine months of 2013 stood at $698 million, or about 20% higher than the same period in 2012, and (2) the tiered structure of the royalty agreement between the two companies, the royalty estimate is pretty solid barring any unforeseen developments. Better yet, Bristol-Myers Squibb has a history of reporting its full year results one full month ahead of Repligen (February vs. March), so investors will be able to accurately gauge the royalty stream for 2013 before management formally discusses results. When the investing world offers up life hacks, you have to take them.

Now we can turn our attention to 2014. How can investors expect the top line to look when it is completely dependent on product revenue?




% Change

Orencia Royalties


$17.87 million


Product Revenue

$51-$54 million

$48 million


Total Revenue

$51-$54 million

$67 million


Source: Piper Jaffray Conference Presentation, Author's calculations

The table above highlights which categories are changing for Repligen in 2014. While product revenue will grow at a 10%-15% clip, the gains won't be obvious by observing the drop in total revenue -- derived completely from the loss of Orencia royalties. It's important to note that we cannot -- and should not -- factor in potential additional milestone payments from the Pfizer license agreement or a potential acquisition of a new product. If either occurs, consider it gravy. If they don't, hey, it's not a big deal.

We've made a reliable revenue estimate for 2014 based on the most current guidance from management and sales data from Bristol-Myers Squibb. That's all we can do with the top line for now, but we'll evaluate the bottom line (and cash) in the next article.

Foolish bottom line

Perspective is always a good thing in investing. For Repligen shareholders, it will be important to digest financial progress in terms of bioprocessing product sales growth and operational efficiency improvements (more in our next article). Yes, income and total revenue will deflate without Orencia royalties from Bristol-Myers Squibb, but that isn't going to affect the company's long term opportunities or the industry trends powering growth. Remember to check back later for a thorough analysis of Repligen's income and cash for 2014.

Is uncertainty keeping you away from Repligen?

Despite a solid analysis and estimate, you may not feel so great about putting your hard-earned money into a stock facing so much uncertainty in 2014. Luckily, while opportunities to get wealthy from a single investment don't come around often, they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or his previous writing.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information